Weiguang Zhao

Weiguang Zhao

Auto-generated profile, based on publicly available information

Weiguang Zhao

14US Imaging Hub, Clinical Pharmacology and Safety Sciences, AstraZeneca, Gaithersburg, Maryland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2003 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
PBPhilip Babij
Philip Babij
WZWeiguang Zhao
Weiguang Zhao
CSClayton Small
Clayton Small
YKYogendra Kharode
Yogendra Kharode
PYPaul J Yaworsky
Paul J Yaworsky
FBFrederick Bex
Frederick Bex
A unique mutation in LRP5 is associated with high bone mass in man. Transgenic mice expressing this LRP5 mutation have a similar phenotype with high bone mass and enhanced strength. These results underscore the importance of LRP5 in skeletal regulation and suggest targets for therapies for bone disease. A mutation (G171V) in the low-density lipoprotein receptor related protein 5 (LRP5) has been associated with high bone mass (HBM) in two independent human kindreds. To validate the role of the mutation, several lines of transgenic mice were created expressing either the human LRP5 G171V substitution or the wildtype LRP5 gene in bone. Volumetric bone mineral density (vBMD) analysis by pQCT showed dramatic increases in both total vBMD (30-55%) and trabecular vBMD (103-250%) of the distal femoral metaphysis and increased cortical size of the femoral diaphysis in mutant G171V transgenics at 5, 9, 17, 26, and 52 weeks of age (p < 0.01 for all). In addition, high-resolution microcomputed tomography (microCT) analysis of the distal femorae and lumbar vertebrae revealed an increase (110-232%) in trabecular bone volume fraction caused by both increased trabecular number (41-74%) and increased trabecular thickness (34-46%; p < 0.01 for all) in the mutant G171V mice. The increased bone mass was associated with significant increases in vertebral compressive strength (80-140%) and the increased cortical size with significant increases in femoral bending strength (50-130%). There were no differences in osteoclast number at 17 weeks of age. However, compared with littermate controls, the mutant G171V transgenic mice showed an increase in actively mineralizing bone surface, enhanced alkaline phosphatase staining in osteoblasts, and a significant reduction in the number of TUNEL-positive osteoblasts and osteocytes. These results suggest that the increased bone mineral density in mutant G171V mice was caused by increased numbers of active osteoblasts, which could in part be because of their increased functional lifespan. While slight bone anabolic activity was observed from overexpression of the wildtype LRP5 gene, it is clear that the G171V mutation, rather than overexpression of the receptor itself, is primarily responsible for the dramatic HBM bone effects. Together, these findings establish the importance of this novel and unexpected role of a lipoprotein receptor in regulating bone mass and afford a new model to explore LRP5 and its recent association with Wnt signaling in bone biology.

24 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJulio C. Chavez
Julio C. Chavez
FFFrancine Foss
Francine Foss
Basem WilliamBasem William
Basem William
JBJonathan Brammer
Jonathan Brammer
SSSonali Smith
Sonali Smith
LSLillian L. Siu
Lillian L. Siu
Purpose: Proliferation of T-follicular helper (TFH) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by TFH, representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT), and recommended phase II dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01–3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29–86) and the median prior lines of therapies was 3 (1–16). Most common grade 3 or 4 adverse events were decreased CD4+ T cells (57%), lymphopenia (22%), anemia (13%), and infusion-related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4+ICOS+ T cells reflecting its effects on TFH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.

2 March 2006 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
JRJohn A. Robinson
John A. Robinson
VSVedrana Susulic
Vedrana Susulic
YLYao‐Bin Liu
Yao‐Bin Liu
CTChanda Taylor
Chanda Taylor
JHJill Hardenburg
Jill Hardenburg
FBFred Bex
Fred Bex

11 October 2021 in Chest
Verified
Journal Article
Open access
PDF file
CMChristopher Mccrae
Christopher Mccrae
JCJennifer Cann
Jennifer Cann
WZWeiguang Zhao
Weiguang Zhao
DCDavid Chain
David Chain
KDKarma Dacosta
Karma Dacosta
AJAndrew Jones
Andrew Jones
TOPIC: Chest Infections


4 April 2023
Verified
Other
Open access
JCJulio C. Chavez
Julio C. Chavez
FFFrancine Foss
Francine Foss
Basem WilliamBasem William
Basem William
JBJonathan Brammer
Jonathan Brammer
SSSonali Smith
Sonali Smith
LSLillian L. Siu
Lillian L. Siu
Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A) Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.